Literature DB >> 22340823

Impact of statin therapy on plaque characteristics as assessed by serial OCT, grayscale and integrated backscatter-IVUS.

Kousuke Hattori1, Yukio Ozaki, Tevfik F Ismail, Masanori Okumura, Hiroyuki Naruse, Shino Kan, Makoto Ishikawa, Tomoko Kawai, Masaya Ohta, Hideki Kawai, Tousei Hashimoto, Yasushi Takagi, Junichi Ishii, Patrick W Serruys, Jagat Narula.   

Abstract

OBJECTIVES: The purpose of this study was to evaluate the effect of statin treatment on coronary plaque composition and morphology by optical coherence tomography (OCT), grayscale and integrated backscatter (IB) intravascular ultrasound (IVUS) imaging.
BACKGROUND: Although previous studies have demonstrated that statins substantially improve cardiac mortality, their precise effect on the lipid content and fibrous cap thickness of atherosclerotic coronary lesions is less clear. While IVUS lacks the spatial resolution to accurately assess fibrous cap thickness, OCT lacks the penetration of IVUS. We used a combination of OCT, grayscale and IB-IVUS to comprehensively assess the impact of pitavastatin on plaque characteristics.
METHODS: Prospective serial OCT, grayscale and IB-IVUS of nontarget lesions was performed in 42 stable angina patients undergoing elective coronary intervention. Of these, 26 received 4 mg pitavastatin after the baseline study; 16 subjects who refused statin treatment were followed with dietary modification alone. Follow-up imaging was performed after a median interval of 9 months.
RESULTS: Grayscale IVUS revealed that in the statin-treated patients, percent plaque volume index was significantly reduced over time (48.5 ± 10.4%, 42.0 ± 11.1%; p = 0.033), whereas no change was observed in the diet-only patients (48.7 ± 10.4%, 50.4 ± 11.8%; p = NS). IB-IVUS identified significant reductions in the percentage lipid volume index over time (34.9 ± 12.2%, 28.2 ± 7.5%; p = 0.020); no change was observed in the diet-treated group (31.0 ± 10.7%, 33.8 ± 12.4%; p = NS). While OCT demonstrated a significant increase in fibrous cap thickness (140 ± 42 μm, 189 ± 46 μm; p = 0.001), such changes were not observed in the diet-only group (140 ± 35 μm, 142 ± 36 μm; p = NS). Differences in the changes in the percentage lipid volume index (-6.8 ± 8.0% vs. 2.8 ± 9.9%, p = 0.031) and fibrous cap thickness (52 ± 32 μm vs. 2 ± 22 μm, p < 0.001) over time between the pitavastatin and diet groups were highly significant.
CONCLUSIONS: Statin treatment induces favorable plaque morphologic changes with an increase in fibrous cap thickness, and decreases in both percentage plaque and lipid volume indexes. Copyright Â
© 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22340823     DOI: 10.1016/j.jcmg.2011.11.012

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN: 1876-7591


  35 in total

Review 1.  MDCT evaluation of atherosclerotic coronary artery disease: what should radiologists know?

Authors:  Hye Rin Kim; Seung Min Yoo; Ji Young Rho; Hwa Yeon Lee; Charles S White
Journal:  Int J Cardiovasc Imaging       Date:  2014-04-01       Impact factor: 2.357

2.  Three-dimensional morphological response of lipid-rich coronary plaques to statin therapy: a serial optical coherence tomography study.

Authors:  Zhao Wang; Young-Seok Cho; Tsunenari Soeda; Yoshiyasu Minami; Lei Xing; Haibo Jia; Aaron Aguirre; Rocco Vergallo; Hang Lee; James G Fujimoto; Bo Yu; Ik-Kyung Jang
Journal:  Coron Artery Dis       Date:  2016-08       Impact factor: 1.439

Review 3.  HDL-targeted therapies: progress, failures and future.

Authors:  Bronwyn A Kingwell; M John Chapman; Anatol Kontush; Norman E Miller
Journal:  Nat Rev Drug Discov       Date:  2014-05-23       Impact factor: 84.694

Review 4.  Stabilization of high-risk plaques.

Authors:  Kohei Takata; Satoshi Imaizumi; Bo Zhang; Shin-Ichiro Miura; Keijiro Saku
Journal:  Cardiovasc Diagn Ther       Date:  2016-08

5.  A simple and rapid method for identification of lesions at high risk for the no-reflow phenomenon immediately before elective coronary stent implantation.

Authors:  Akira Suda; Shigeto Namiuchi; Tomohiro Kawaguchi; Taro Nihei; Toru Takii; Kenya Saji; Tadashi Sugie; Atsushi Kato; Hiroaki Shimokawa
Journal:  Heart Vessels       Date:  2016-03-02       Impact factor: 2.037

Review 6.  Bridging the gap for lipid lowering therapy: plaque regression, coronary computed tomographic angiography, and imaging-guided personalized medicine.

Authors:  Alan C Kwan; Konstantinos N Aronis; Veit Sandfort; Roger S Blumenthal; David A Bluemke
Journal:  Expert Rev Cardiovasc Ther       Date:  2017-07-06

Review 7.  Clinical classification of plaque morphology in coronary disease.

Authors:  Fumiyuki Otsuka; Michael Joner; Francesco Prati; Renu Virmani; Jagat Narula
Journal:  Nat Rev Cardiol       Date:  2014-04-29       Impact factor: 32.419

8.  Histopathologic characteristics of atherosclerotic coronary disease and implications of the findings for the invasive and noninvasive detection of vulnerable plaques.

Authors:  Jagat Narula; Masataka Nakano; Renu Virmani; Frank D Kolodgie; Rita Petersen; Robert Newcomb; Shaista Malik; Valentin Fuster; Aloke V Finn
Journal:  J Am Coll Cardiol       Date:  2013-03-12       Impact factor: 24.094

Review 9.  Prediction of cardiovascular outcomes by imaging coronary atherosclerosis.

Authors:  Faraz Pathan; Kazuaki Negishi
Journal:  Cardiovasc Diagn Ther       Date:  2016-08

10.  Statins use and coronary artery plaque composition: results from the International Multicenter CONFIRM Registry.

Authors:  Ryo Nakazato; Heidi Gransar; Daniel S Berman; Victor Y Cheng; Fay Y Lin; Stephan Achenbach; Mouaz Al-Mallah; Matthew J Budoff; Filippo Cademartiri; Tracy Q Callister; Hyuk-Jae Chang; Ricardo C Cury; Kavitha Chinnaiyan; Benjamin J W Chow; Augustin Delago; Martin Hadamitzky; Joerg Hausleiter; Philipp Kaufmann; Erica Maffei; Gilbert Raff; Leslee J Shaw; Todd C Villines; Allison Dunning; Gudrun Feuchtner; Yong-Jin Kim; Jonathon Leipsic; James K Min
Journal:  Atherosclerosis       Date:  2012-08-24       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.